A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
Status:
Recruiting
Trial end date:
2024-01-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-response of bermekimab efficacy in
participants with moderate to severe Hidradenitis Suppurativa (HS).